MK-7684
Total Payments
$15.1M
Transactions
3,541
Doctors
4
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $3.5M | 2,225 | 4 |
| 2019 | $4.4M | 342 | 4 |
| 2018 | $6.1M | 448 | 0 |
| 2017 | $1.1M | 526 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $14.9M | 3,476 | 98.8% |
| Consulting Fee | $178,180 | 65 | 1.2% |
Payments by Type
Research
$14.9M
3,476 transactions
General
$178,180
65 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Phase I Trial of MK-7684 as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumor | Merck Sharp & Dohme Corporation | $14.9M | 0 |
Top Doctors Receiving Payments for MK-7684
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $15.1M
- Total Doctors 4
- Transactions 3,541
About MK-7684
MK-7684 is a drug associated with $15.1M in payments to 4 healthcare providers, recorded across 3,541 transactions in the CMS Open Payments database. The primary manufacturer is Merck Sharp & Dohme Corporation.
Payment data is available from 2017 to 2020. In 2020, $3.5M was paid across 2,225 transactions to 4 doctors.
The most common payment nature for MK-7684 is "Unspecified" ($14.9M, 98.8% of total).
MK-7684 is associated with 1 research study, including "Phase I Trial of MK-7684 as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumor" ($14.9M).